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CLINICAL AND POPULATION SCIENCES
Risk and Secondary Prevention of Stroke 
Recurrence
A Population-Base Cohort Study
Clare Flach , PhD; Walter Muruet, MD; Charles D.A. Wolfe, MD; Ajay Bhalla, MD; Abdel Douiri, PhD
BACKGROUND AND PURPOSE: With recent advances in secondary prevention management, stroke recurrence rates may have 
changed substantially. We aim to estimate risks and trends of stroke recurrence over the past 2 decades in a population-
based cohort of patients with stroke.
METHODS: Patients with a first-ever stroke between 1995 and 2018 in South London, United Kingdom (n=6052) were 
collected and analyzed. Rates of recurrent stroke with 95% CIs were stratified by 5-year period of index stroke and etiologic 
TOAST (Trial of ORG 10172 in Acute Stroke Treatment) subtype. Cumulative incidences were estimated and multivariate Cox 
models applied to examine associations of recurrence and recurrence-free survival.
RESULTS: The rate of stroke recurrence at 5 years reduced from 18% (95% CI, 15%–21%) in those who had their stroke in 
1995 to 1999 to 12% (10%–15%) in 2000 to 2005, and no improvement since. Recurrence-free survival has improved 
(35%, 1995–1999; 67%, 2010–2015). Risk of recurrence or death is lowest for small-vessel occlusion strokes and other 
ischemic causes (36% and 27% at 5 years, respectively). For cardioembolic and hemorrhagic index strokes around half of 
first recurrences are of the same type (54% and 51%, respectively). Over the whole study period a 54% increased risk of 
recurrence was observed among those who had atrial fibrillation before the index stroke (hazard ratio, 1.54 [1.09–2.17]).
CONCLUSIONS: The rate of recurrence reduced until mid-2000s but has not changed over the last decade. The majority of 
cardioembolic or hemorrhagic strokes that have a recurrence are stroke of the same type indicating that the implementation 
of effective preventive strategies is still suboptimal in these stroke subtypes.
Key Words: atrial fibrillation ◼ prevalence ◼ risk factors ◼ secondary prevention
It is estimated from a global meta-analysis in 2011 that 11% of individuals will have a recurrence within a year of their first stroke and 26% within 5 years. However, 
most of the studies included (12/13) provided follow-up 
to only 1-year poststroke with only 7 having information 
on recurrence to 5 years.The authors report that the rate 
of recurrence at 5 years halved over the period of the 
studies (1961–2006).1
Furthermore, systematic reviews report that secondary 
prevention measures (antithrombotic, statin, and antihyper-
tensive therapies) can reduce the risk of secondary vascular 
events by 20% to 30%.2–5 This suggests that there may 
have been large improvements in recent years in reducing 
recurrence after stroke. Observational studies have also 
described this pattern through the 1990s and 2000s.6–10 
However, with the increasing prevalence of risk factors such 
as diabetes mellitus as well as suboptimal uptake of preven-
tative therapies11,12 these improvements may be at risk.
There is some evidence that the type of initial stroke has 
an impact on recurrence,13,14 though this is not shown in all 
studies,15 mainly because of limitation of the sample size. 
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risk for recurrence while individuals with lacunar stroke 
and hemorrhagic stroke have a smaller risk for recurrent 
stroke13 but higher risk of death compared with nonisch-
emic strokes.16 There is a need to understand further the 
association between initial stroke and subsequent stroke to 
be able to recommend more tailored prevention and moni-
toring strategies to reduce the risk of stroke recurrence.
In this study, we examine risks and trends over the 
past 23 years, of recurrence and death after stroke in 
a population-based study and identify patient groups at 
risk of stroke recurrence including age, sex, and etio-
logic subtype.
METHODS
Because of the sensitive nature of the data collected for this 
study, requests to access the data set from qualified research-
ers trained in human subject confidentiality protocols may be 
requested through the below link: https://www.kcl.ac.uk/lsm/
research/divisions/hscr/research/groups/stroke/index.aspx
Study Population
The South London Stroke Register (SLSR), established in 1995, 
is an ongoing multi-ethnic, urban-based population register of all 
first-ever strokes in a defined population of inner London, includ-
ing 22 electoral wards in Lambeth and Southwark. The total 
source population of the SLSR area was 357 308 individuals in 
the 2011 Census; their self-reported race was as follows: 56% 
white, 25% black (7% black Caribbean, 14% black African, and 
4% black other), and 18% of other ethnic backgrounds. All indi-
viduals are included in the analyses of temporal trends in recur-
rence and mortality. Individuals recruited to the cohort between 
January 2000 and December 2018 were included in the analy-
ses of stroke subtype, a subgroup of patients from 2005 onwards 
were included for analyses of poststroke care. Individuals were 
followed up at 3 months and then on an annual basis.
Case Ascertainment
Standardized criteria were applied to ensure completeness of 
case ascertainment, including multiple overlapping sources of 
notification. All patients with a suspected diagnosis of stroke or 
transient ischemic attack documented in different hospital and 
community-based information sources were investigated for 
study eligibility. Patients admitted to hospitals serving the study 
area were identified by regular reviews of acute wards admitting 
patients with stroke, weekly checks of brain imaging referrals, and 
monthly reviews of bereavement officer and bed manager records. 
Additionally, national data on patients admitted to any hospital in 
England and Wales with a diagnosis of stroke were also screened 
for additional patients. To identify patients not admitted to hospital, 
all general practitioners within and on the borders of the study area 
were contacted regularly and asked to notify the SLSR of patients 
with stroke. Regular communication with general practitioners 
was achieved by telephone contact and quarterly newsletters. 
Referral of nonhospitalized patients with stroke to a neurovascular 
outpatient clinic (from 2003) or domiciliary visit to patients by the 
study team was also available to general practitioners. Community 
therapists were contacted every 3 months. Death certificates were 
checked regularly. Completeness of case ascertainment has been 
estimated at 88% by a multinomial-logit capture-recapture model 
using the methods described elsewhere.17
Definitions
Stroke was defined according to the World Health Organization 
criteria; International Classification of Diseases-Tenth Revision 
codes I60.-, I61.-, I63.-, and I64 were included. As per this defini-
tion, patients who died within 24 hours of stroke were included 
but those who had an event lasting less than 24 hours were 
classified as TIAs and, therefore, excluded from the register. 
Stroke recurrence was defined by the same criteria as the initial 
stroke. Both ischemic and hemorrhagic stroke recurrences were 
recorded. Only recurrences 21 days after the initial event, or if 
earlier, clearly in a different vascular territory were included.18
Pathological stroke subtype was defined by brain imag-
ing, lumbar puncture, or postmortem autopsy. The proportion of 
patients who received any brain imaging ranged from 95% in 
2000 to 2003 to 100% to date. Neuroradiology or necropsy 
results classified strokes into ischemic stroke, primary intracere-
bral hemorrhage, or subarachnoid hemorrhage. Ischemic strokes 
were further investigated according to 2 stroke subtypes: The 
Oxfordshire Community Stroke Project classification19 and the 
modified TOAST classification (Trial of ORG 10172 in Acute 
Stroke Treatment).20 The Oxfordshire Community Stroke Project 
contains 4 subtypes according to clinical features: lacunar infarct, 
total anterior circulation infarcts, partial anterior circulation infarcts, 
and posterior circulation infarcts. Modified TOAST denotes 5 
pathogenetic subtypes: large artery atherosclerosis, cardioembo-
lism, small-vessel occlusion (SVO), other determined pathogenesis 
and no pathogenesis identified. Data with modified TOAST clas-
sification were collected only after the year 1999. Additionally, we 
classify hemorrhagic strokes as primary intracerebral hemorrhage 
or subarachnoid hemorrhage. Assignment to each classification 
was done by the senior stroke consultant acting as clinical lead on 
the study. Classification was based on clinical history, brain imag-
ing (computed tomography and magnetic resonance imaging), 
vascular imaging (carotid doppler ultrasound, computed tomogra-
phy angiography, magnetic resonance angiography), cardiac moni-
toring, and echocardiography. In our study cohort, 95% of patients 
had a brain scan (90% computed tomography, 25% MRI), 63% 
had at least one modality of vascular imaging, 81% had cardiac 
monitoring, and 40% had echocardiography.
The SLSR received notification of deaths and associated 
death records from National Health Service digital providing 
the date and cause.
Data Collection
At the time of the index stroke, information was collected by 
highly trained fieldworkers contemporaneously from medical 
records and complemented with patient interview. Information 
was collected on diagnoses before the stroke of hypertension, 
TIA, atrial fibrillation, MI, diabetes mellitus, and other medical 
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Table 1. Description of Sample at Baseline (Stroke Onset)
Variable Category Total 1995–2018
Total  6052





Age group <65 y 2082(34%)
65–74 y 1436 (24%)
75–84 y 1618 (27%)
85 y+ 916 (15%)
Sex Female 2940 (49%)
Ethnicity White 4001 (68%)
Black 1528 (26%)
Other 378 (6%)
Socio-economic group Nonmanual 928 (18%)
Manual 2040 (40%)
Economically inactive 2149 (43%)
Ischemic/hemorrhagic Ischemic 4353 (72%)
Hemorrhagic 1040 (17%)
Unknown 659 (11%)
TOAST classification of ischemic strokes Large artery atherosclerosis 505 (16%)
Cardioembolism 855 (27%)
Small-vessel occlusion 828 (26%)
Ischemic stroke of other cause 82 (3%)
Ischemic stroke of multiple possible causes 93 (3%)
Cryptogenic (unknown cause) 158 (2%)
Ischemic stroke of undetermined cause 624 (20%)
Unknown 578
Not done (pre 2000) 1577









Risk factors (diagnosed before first stroke)
 Transient ischemic attack Yes 625 (11%)
 Hypertension Yes 3760 (65%)
 Diabetes mellitus Yes 1237 (21%)
 Myocardial infarction Yes 628 (11%)
 Atrial fibrillation Yes 1040 (18%)
 Current smoker Yes 1701 (31%)
Stroke severity
 Glasgow Coma Scale Severe (<8) 793 (14%)
 Motor deficit Yes 4187 (76%)
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conditions not considered in this analysis, treatments received 
in hospital and prescriptions at discharge. Attendance by a spe-
cialist stroke physician during hospitalization and whether they 
were seen in a stroke unit was recorded.
Ethics
Written informed consent and assent, when appropriate, were 
obtained from all participants or from a relative for the partici-
pants who were too impaired to provide written consent. Ethical 
approval for the study was obtained from the ethics committees 
of Guy’s and St Thomas’ Hospital Trust, King’s College Hospital, 
Queens Square, and Westminster Hospital (London).
Statistical Methods
A description of the cohort at the time of their first stroke and a 
comparison of stroke subtype between initial stroke and recur-
rent stroke is reported using frequencies and percentages. The 
cumulative risk of recurrence and the combined outcome of 
recurrence or death occurring by 3 months, 1-, 5-, and 10-years 
were produced from the failure function using Kaplan-Meier 
estimates. Cumulative risk is presented overall, by year group 
and stroke subtype. The cumulative incidence of recurrence is 
also reported using a competing risks analysis to account for 
mortality before the event. Associations between risk factors 
and outcome were tested across the full follow-up period using 
cox proportional hazards models adjusting for all baseline fac-
tors considered. The risk factors considered were prespecified, 
and all were included in adjusted regression models. To assess 
the effect of subtype, we include only index strokes since 2000 
adjusting for all covariates. Index strokes occurring since 2005 
are used to look at poststroke treatment where we do not adjust 
for demographics or prestroke risk factors due to small number 
of events. We repeat the analysis for recurrence-free survival 
analyzing the time to recurrence or death. Statistical analyses 
and graphics were performed using Stata Version 14.2.
RESULTS
A total of 6052 individuals were registered on the SLSR 
between January 1995 and December 2018. A third 
(n=2082, 34%) were under 65 years at the time of their 
first stroke and 2534 (42%) were over 75 years, 2940 
(49%) are female, 1906 (31%) are of nonwhite ethnic-
ity. Seventy-one percent of first strokes (4326) were 
ischemic, and the most prevalent risk factor before the 
stroke was hypertension (3760, 65%). Further details of 
the population are presented in Table 1.
Stroke Recurrence
During follow-up 650 individuals had at least one stroke 
recurrence (21.4 per 1000 person-years), including both 
ischemic and hemorrhagic. The median follow-up time 
for the stroke recurrence analysis was 3.0 years (range: 
1 day to 22·5 years) with a total of 30 412 person-years 
of follow-up. The cumulative risk of a stroke recurrence 
decreased between 1995 and 2005 with little change 
since (Table 2, Figure [A]). Risk of recurrence at 5 years 
was 18% (95% CI, 15%–21%) for first strokes between 
1995 to 1999 dropping to 12% (10%–15%) for first 
strokes between 2000 and 2004 and remaining at 
around 10% (9%–13%) for first strokes since 2005. 
When accounting for death as a competing risk the 
5-year recurrence rate is lower at 8.7% (8.0%–9.4%) 
and the 10-year recurrence at 11.2% (10.4%–12.1%).
Recurrence-Free Survival
During the follow-up period, 4035 individuals had a 
recurrence or died (133 per 1000 person-years). The 
median follow-up time for the stroke recurrence analy-
sis was 3·0 years with a total of 30 402 person-years of 
follow-up. The cumulative risk of recurrence or death by 
5 years has reduced from 65% (63%–68%) in 1995 to 
1999 to 43% (40%–46%) for first strokes occurring in 
2010 to 2015.
Poststroke treatments from 2005 onwards Total 2005–2018
 Stroke unit Yes 2375 (81%)
 Seen a stroke specialist physician Yes 2789 (92%)
 Seen a physiotherapist Yes 2489 (84%)
 Seen an occupational therapist Yes 2258 (76%)
 Seen a speech therapist Yes 2042 (69%)
 Seen all above Yes 1808 (62%)
Medications in first 3 mo
 Antihypertensive Yes 1716 (58%)
 Antiplatelet Yes 1723 (59%)
 Anticoagulant Yes 504 (17%)
 Cholesterol-lowering Yes 1754 (60%)
LACI indicates lacunar infarct; PACI, partial anterior circulation infarct; PICH, primary intracerebral hemorrhage; POCI, posterior circulation 
infarct; SAH, subarachnoid hemorrhage; TACI, total anterior circulation infarct; and TOAST, Trial of ORG 10172 in Acute Stroke Treatment.
Table 1. Continued
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Stroke Subtypes as a Risk Factor
Etiologic TOAST stroke subtypes were collected since 
2000 and so further analysis by type is restricted to 
this time period. There is no evidence of an associa-
tion between TOAST subtype and recurrence in either 
crude analysis (Table 2), adjusted for prestroke risk fac-
tors and stroke severity (Table 3) or accounting for death 
as a competing risk (data not shown). When considering 
the combined outcome of recurrence or death individu-
als with a cardioembolic stroke have the worst progno-
sis (63%, 59%–66% recurrence or death by 5 years, 
Table 2 unadjusted). Risk of recurrence or death is higher 
for cardioembolic (hazard ratio [HR], 1.48 [1·25–1.74]), 
large artery atherosclerosis (HR, 1.34 [1.13–1.58), and 
primary intracerebral hemorrhage (HR, 1.29 [1.06–1.55]) 
as well as for undetermined ischemic strokes (HR, 1.42 
[1.21–1.66]) compared with SVO after adjustment for 
prestroke risk factors and severity (Table 3).
Risk of recurrence seems to be reducing in large 
artery atherosclerosis and ischemic stroke of unknown 
cause since 2000 while remaining at a similar level over 
time in cardioembolic and SVO strokes. However, there is 
no significant interaction between subtype and time indi-
cating that there is no evidence of a difference in time 
trends between subtypes.
Overall, comparing ischemic to primary intracerebral 
hemorrhage and subarachnoid hemorrhage strokes 
indicates that there is no difference between them in 
terms of recurrence rates but subarachnoid hemorrhage 
strokes have the best recurrence-free survival with no 
difference observed between ischemic and primary intra-
cerebral hemorrhage (Figure).
The largest proportion of first recurrent strokes are 
the same subtype as their index stroke (Table 4). How-
ever, only for cardioembolic stroke and hemorrhage are 
the majority of first recurrences of the same type (54% 
and 51%, respectively). There is variation between the 
index and recurrent stroke subtype, only 26% of large 
artery atherosclerotic index strokes that have a recur-
rence are of the same classification and 35% of SVO 
index strokes have an SVO recurrence (Table 4).
Table 2. Cumulative Incidence of Recurrence and Recurrence or Death
Recurrence Recurrence or Death
3 Months 1 Year 5 Years 10 Years 3 Months 1 Year 5 Years 10 Years
















Year of index stroke
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Other Stroke Risk Factors
Table 3 shows that older age, prior atrial fibrillation, 
prior hypertension, and smoking are risk factors for 
a second stroke after full adjustment. There is a sug-
gestion that being of black ethnicity increases the 
risk of recurrence compared with white patients but is 
associated with a reduced risk of recurrence or death 
compared with white ethnicity (HR, 0.74 [0.65–0.84]). 
We observe no evidence that having had a myocardial 
infarction before the index stroke or the severity of 
stroke are associated with risk of recurrence but they 
are associated with risk of the combined recurrence or 
death outcome.
In subgroup analyses of index strokes occurring since 
2005, although being treated in a stroke unit, seen by 
a stroke specialist and secondary prevention medica-
tions tend to suggest a reduced risk of recurrence only 
antithrombotics show a statistically significantly asso-
ciation (Table 5). There is little change in the type of 
strokes seen over time, though there is a suggestion of 
an increase in the proportion of cardioembolic strokes 
in the past 5 years (Figure I in the Data Supplement). 
Prescription of secondary preventions medications as 
well as treatment by a stroke specialist and in a stroke 
unit are associated with a reduced risk of the joint out-
come recurrence or death. These results are minimally 
adjusted for age, Glasgow Coma Scale, and prestroke 
risk factors as the number of events limits the variables 
that can be included. There has been little change in 
secondary prevention prescription rates since 2005 
(Figure I in the Data Supplement). Prescription of anti-
thrombotics has stayed at around 70%, antihyperten-
sives and statins at around 60%.
We also find that the increased risk of recurrence or 
death due to having a previous diagnosis of atrial fibrilla-
tion remains after adjustment for treatments received. Of 
the 488 individuals who had been diagnosed with atrial 
fibrillation before their index stroke and reached dis-
charge from hospital, 123 (25%) were prescribed anti-
coagulants and no antiplatelets at discharge or within 3 
months, 154 (32%) were prescribed antiplatelets and no 
anticoagulants at discharge or within 3 months and 52 
Figure. Failure function for recurrence and recurrence-free survival by year and subtype.  
A, Stroke recurrence by year of first stroke; (B) recurrence-free survival by year of first stroke; (C) stroke recurrence by type of stroke; and (D) 
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(11%) received both. One hundred fifty-nine individuals 
(33%) received neither.
DISCUSSION
We have extended previous SLSR reports18, 21 by 
estimating trends over the past 20 years in stroke 
recurrence and explored associations with different 
exposures including demographics and stroke etiologic 
subtypes. Recurrence rates after first strokes reduced 
between 1995 and 2005 but have remained at 
approximately the same level since then. Recurrence-
free survival has continued to improve, driven mainly 
by a reduction in mortality. Although cardioembolic or 
hemorrhagic subsequent strokes are largely prevent-
able, the majority of recurrences occurring after these 
strokes are the same subtype.
The reduction in recurrence seen at the beginning 
of our study suggests that secondary prevention mea-
sures have been effective, and recurrences are now 
being maintained at a low level, a trend reported in other 
studies which also observed only small reductions since 
2000.22 Despite this flattening in recurrence rates the 
joint outcome of recurrence-free survival continues to 
improve. Since this is not driven by stroke recurrences, 
it may be that general health is improving or that treat-
ment of prevalent vascular comorbidities such as MI are 
continuing to improve.23
Alternatively, those with a cardioembolic or hemor-
rhagic stroke who have a recurrence are most likely 
to have a repeated stroke of the same type, in our 
study sample. This same trend was reported in the 
SLSR previously, but now with a larger sample size.21 
Further exploration of the subgroup that have differ-
ence recurrence subtype to their index stroke is not 
Table 3. Prestroke Risk Factors for Stroke Recurrence Including TOAST Classification
Recurrence Recurrence or Death
Variable Category HR (95% CI), P Value HR (95% CI), P Value
Year of first stroke 2000–2004 vs 1995–1999 0.96 (0.71–1.29), 0.773 0.83 (0.74–0.94), 0.004
 2005–2009 vs 1995–1999 1.09 (0.67–1.76), 0.738 0.71 (0.58–0.86), 0.001
 2010–2015 vs 1995–1999 0.95 (0.53–1.69), 0.860 0.55 (0.43–0.71), <0.001
Stroke subtype by TOAST Large artery atherosclerosis vs SVO 1.12 (0.76–1.65), 0.579 1.34 (1.13–1.58), 0.001
 Cardioembolism vs SVO 1.24 (0.85–1.82), 0.258 1.48 (1.25–1.74), <0.001
 Ischemic stroke—other vs SVO 0.99 (0.43–2.31), 0.989 0.96 (0.61–1.50), 0.854
 Ischemic stroke—undetermined vs SVO 1.21 (0.84–1.74), 0.307 1.42 (1.21–1.66), <0.001
 PICH vs SVO 1.42 (0.92–2.19), 0.111 1.29 (1.06–1.55), 0.009
 SAH vs SVO 0.66 (0.26–1.71), 0.397 0.72 (0.48–1.09), 0.118
Age group 65–74y vs <65 y 1.47 (1.06–2.04), 0.021 2.47 (2.10–2.90), <0.001
 75–84y vs <65 y   1.85 (1.32–2.60), <0.001 3.54 (3.01–4.16), <0.001
 85y+ vs <65 y   2.52 (1.62–3.93), <0.001 6.74 (5.59–8.13), <0.001
Sex Female vs male 1.06 (0.83–1.36), 0.618 0.88 (0.79–0.98), 0.015
Ethnicity Black vs white 1.28 (0.96–1.70), 0.090 0.75 (0.66–0.86), <0.001
 Other vs white 1.30 (0.83–2.03), 0.257 0.67 (0.53–0.84), 0.001
Socio-economic group Manual vs nonmanual 1.17 (0.83–1.63), 0.370 1.04 (0.90–1.19), 0.626
 Economically inactive vs nonmanual 0.87 (0.56–1.36), 0.542 1.12 (0.94–1.33), 0.201
Risk factors (diagnosed before 1st stroke)  
Transient ischemic attack Yes vs no 1.29 (0.90–1.85), 0.162 1.13 (0.97–1.32), 0.107
Hypertension Yes vs no 1.45 (1.09–1.94), 0.011 0.99 (0.89–1.11), 0.921
Diabetes mellitus Yes vs no 0.96 (0.71–1.29), 0.770 1.18 (1.04–1.34), 0.011
Myocardial infarction Yes vs no 0.95 (0.63–1.43), 0.790 1.17 (1.00–1.38), 0.050
Atrial fibrillation Yes vs no 1.54 (1.09–2.17), 0.015 1.25 (1.09–1.45), 0.002
Smoker or ex-smoker Yes vs no 1.37 (1.03–1.81), 0.028 1.25 (1.11–1.42), <0.001
Stroke severity
Glasgow Coma Scale Mild/moderate vs severe 1.02 (0.49–2.15), 0.948 2.92 (2.45–3.50), <0.001
Motor deficit Yes vs no 0.93 (0.71–1.23), 0.610 1.27 (1.11–1.45), 0.001
Incontinence Yes vs no 0.89 (0.66–1.21), 0.456 1.59 (1.41–1.79), <0.001






















Flach et al Risk and Secondary Prevention of Stroke Recurrence
2442  August 2020 Stroke. 2020;51:2435–2444. DOI: 10.1161/STROKEAHA.120.028992
possible due to limited numbers. This may suggest that 
the secondary prevention measures are not having the 
impact we would expect, maybe due to low coverage, 
complication with these vascular subtypes or problems 
with adherence. A previous SLSR analysis found 60% 
of patients with stroke with AF were not treated with 
anticoagulants11 and more recent reports suggest that 
this figure is 46% across the United Kingdom.12 Here 
we have observed that 33% of patients with stroke 
with a previous diagnosis of AF do not receive either 
anticoagulants or antiplatelets at discharge. This is a 
particular concern as we find that having AF is one of 
the main indicators of a poor outcome after stroke, 
a finding reiterated in other studies.24,25 Patients with 
stroke are also failing to receive treatment for other 
health issues, for example only 60% to 70% of those 
with hypertension receive the appropriate treatment 
and 70% to 75% of those with diabetes mellitus.11 
Ensuring treatment for these patient groups could 
have a positive impact on their outcomes, though this 
has not been tested explicitly in this study. In addi-
tion, there may be issues with adherence, we only have 
information on prescription and so cannot analyze this 
further; but it is likely that we will underestimate the 
true effect of taking the medication. It is hypothesized 
that patient adherence and the success of second-
ary prevention strategies may be improved by early 
initiation in hospital.26 This is supported indirectly by 
our finding that those who are seen by a specialist 
stroke physician or in a stroke unit have better survival 
though we do not see a significant association with 
recurrence.
Having a previous diagnosis of AF is a risk factor 
for a second stroke, supporting findings of a Swedish 
cohort.25 There is some evidence that being of black 
ethnicity increases your risk of recurrence compared 
with patients with stroke of white ethnicity, though the 
opposite is true when it comes to the joint outcome of 
recurrence or death. In the US black minority groups, 
having a stroke are less likely to receive expected 
acute interventions compared with their white counter-
parts as well as having increased mortality.27 However, 
analyses of the SLSR data found the opposite, that 
Caribbean/African stroke patients were more likely to 
be admitted to hospital or to a stroke unit.11
Table 4. Recurrence TOAST/Hemorrhagic Classification by Index TOAST/Hemorrhagic Classification, 2000–2018
TOAST/Hemorrhagic 

















Undetermined PICH SAH Unknown
Large artery 
atherosclerosis
330 (90%) 37 (10%) 8 (21%) 3 (8%) 5 (13%) 1 (3%) 13 (34%) 1 (3%) 0 6 (16%)
Cardioembolism 528 (91%) 53 (9%) 1 (2%) 29 (55%) 1 (2%) 0 9 (17%) 3 (6%) 1 (2%) 9 (17%)
Small-vessel occlusion 496 (91%) 50 (9%) 3 (6%) 8 (16%) 18 (35%) 3 (6%) 7 (14%) 2 (4%) 0 10 (20%)
Ischemic stroke of  
other cause
44 (88%) 6 (12%) 1 (17%) 3 (50%) 0 0 1 (17%) 0 0 1 (17%)
Ischemic stroke of 
undetermined cause
549 (92%) 50 (8%) 1 (2%) 7 (14%) 6 (12%) 2 (4%) 18 (36%) 5 (10%) 1 (2%) 10 (20%)
PICH 331 (91%) 33 (9%) 0 3 (9%) 4 (12%) 0 2 (6%) 19 (56%) 0 6 (18%)
SAH 109 (94%) 7 (6%) 0 0 0 4 (57%) 1 (14%) 1 (14%) 1 (14%) 0
Total 2,387 (91%) 236 (9%) 14 (6%) 53 (22%) 34 (14%) 10 (4%) 51 (21%) 32 (13%) 3 (1%) 42 (18%)
PICH indicates primary intracerebral hemorrhage; SAH, subarachnoid hemorrhage; and TOAST, Trial of ORG 10172 in Acute Stroke Treatment.
Table 5. Poststroke Treatment Associated With Recurrence and Death, 2005 Onwards
 
Recurrence Recurrence or Death
HR (95% CI), P Value HR (95% CI), P Value
Treated in stroke unit Yes vs no 0.76 (0.54–1.08), 0.129 0.69 (0.60–0.79), <0.001
Seen by specialist stroke physician Yes vs no 0.69 (0.45–1.07), 0.099 0.72 (0.60–0.86), <0.001
Thrombolysis Yes vs no 0.94 (0.62–1.44), 0.792 1.06 (0.90–1.26), 0.472
Cholesterol-lowering within 3 months Yes vs no 0.84 (0.62–1.13), 0.253 0.44 (0.39–0.50), <0.001
Antihypertensive within 3 months Yes vs no 0.84 (0.61–1.18), 0.320 0.39 (0.34–0.44), <0.001
Antiplatelet within 3 months Yes vs no 0.85 (0.63–1.14), 0.266 0.51 (0.46–0.58), <0.001
Anticoagulant within 3 months Yes vs no 0.83 (0.58–1.20), 0.320 0.67 (0.57–0.78), <0.001
AF indicates atrial fibrillation; HR, hazard ratio; MI, myocardial infarction; and TIA, transient ischaemic attack.




 http://ahajournals.org by on January 29, 2021
CLINICAL AND POPULATION 
SCIENCES
Flach et al Risk and Secondary Prevention of Stroke Recurrence
Stroke. 2020;51:2435–2444. DOI: 10.1161/STROKEAHA.120.028992 August 2020  2443
There are many strengths in our study. It is a large 
study of patients with stroke with long-term follow-up, 
both the primary outcome recurrence is captured through 
the stroke register as well as by follow-up of patients and 
is well completed. The risk factor analysis was conducted 
in a large cohort, though only those with complete infor-
mation on all covariates could be included.
We have considered only baseline risk factors of 
recurrence, further analyses investigating the impact 
of secondary prevention measures after discharge and 
adherence would be of interest. This would benefit 
from linking to other resources such as primary care 
and cardiovascular disease registers to get a more 
accurate presentation of other cardiovascular out-
comes such as myocardial infarction.
In conclusion, the rate of recurrence reduced until 
2005 but has not changed since. The majority of car-
dioembolic or hemorrhagic strokes recurrences are of 
the same subtype suggesting that the implementation 
of effective preventive strategies as detailed in the 
National Clinical Guidelines for Stroke is suboptimal in 
these stroke subtypes.
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